Single injection of cd34+ progenitor-derived dendritic cell vaccine can lead to induction of t-cell immunity in patients with stage iv melanoma

A. Karolina Palucka, Madhav V. Dhodapkar, Sophie Paczesny, Susan Burkeholder, Knut M. Wittkowski, Ralph M. Steinman, Joseph Fay, Jacques Banchereau

Research output: Contribution to journalArticle

55 Scopus citations


There is evidence that dendritic cell (DC) vaccines induce tumor-specific immune responses that correlate with clinical responses. Little is known, however, about the kinetics of T-cell responses to antigens presented on DC vaccines. The authors vaccinated 18 HLA A*0201+ patients with stage IV melanoma with CD34 HPC-derived DCs pulsed with six antigens: influenza matrix peptide (Flu-MP), KLH, and peptides derived from the four melanoma antigens: MART-1/Melan A, gp100, tyrosinase, and MAGE-3. A single DC vaccination was sufficient for induction of KLH-specific CD4 T-cell responses in five patients and Flu-MP-specific CD8 T-cell responses in eight patients. A single DC vaccine was sufficient for induction of tumor-specific effectors to at least one melanoma antigen in five patients. Thus, a single injection of CD34 HPC-derived DCs can lead to rapid immune response to CD4 epitopes or to melanoma antigens.

Original languageEnglish (US)
Pages (from-to)432-439
Number of pages8
JournalJournal of Immunotherapy
Issue number5
StatePublished - Jan 1 2003



  • Cancer
  • Dendritic cells
  • Immunotherapy
  • Tumor immunology
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Cite this